(Q35106861)

English

Cognitive and affective changes in mild to moderate Alzheimer's disease patients undergoing switch of cholinesterase inhibitors: a 6-month observational study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Cognitive and affective changes in mild to moderate Alzheimer's disease patients undergoing switch of cholinesterase inhibitors: a 6-month observational study (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Alzheimer's disease

0 references

object named as

Sandro Sorbi

4

0 references

Carlo Caltagirone

2

object named as

Carlo Caltagirone

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

author name string

Gianfranco Spalletta

1

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Alessandro Padovani

3

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Mahmood Attar

5

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Delia Colombo

6

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Luca Cravello

7

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

E V O L U T I O N study Working Group

8

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

language of work or name

0 references

publication date

19 February 2014

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

e89216

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

copyright license

Creative Commons Attribution 4.0 International

19 February 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Rivastigmine patch ameliorates depression in mild AD: preliminary evidence from a 6-month open-label observational study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3929703

9 July 2018

GOOD or BAD responder? Behavioural and neuroanatomical markers of clinical response to donepezil in dementia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3929703

9 July 2018

Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3929703

9 July 2018

Rivastigmine lowers Aβ and increases sAPPα levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3929703

9 July 2018

Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3929703

9 July 2018

Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3929703

9 July 2018

Sertraline for the treatment of depression in Alzheimer disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3929703

9 July 2018

A novel effect of rivastigmine on pre-synaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3929703

9 July 2018

Disease-modifying approach to the treatment of Alzheimer's disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3929703

9 July 2018

Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3929703

9 July 2018

Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3929703

9 July 2018

Rivastigmine in the treatment of Alzheimer's disease: an update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3929703

9 July 2018

Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3929703

9 July 2018

National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3929703

9 July 2018

The Neuropsychiatric Inventory: assessing psychopathology in dementia patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3929703

9 July 2018

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3929703

9 July 2018

“Mini-mental state”

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3929703

9 July 2018

Changes in brain cholinesterases in senile dementia of Alzheimer type

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3929703

9 July 2018

Occurrence of neuropsychiatric symptoms and psychiatric disorders in mild Alzheimer's disease and mild cognitive impairment subtypes.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0089216

21 January 2018

Neuropsychiatric symptoms and syndromes in a large cohort of newly diagnosed, untreated patients with Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0089216

21 January 2018

Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0089216

21 January 2018

Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0089216

21 January 2018

Switching cholinesterase inhibitor therapy in Alzheimer's disease--donepezil to rivastigmine, is it worth it?

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0089216

21 January 2018

Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0089216

21 January 2018

The persistence of neuropsychiatric symptoms in dementia: the Cache County Study.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0089216

21 January 2018

A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0089216

21 January 2018

Butyrylcholinesterase in the life cycle of amyloid plaques.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0089216

21 January 2018

Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0089216

21 January 2018

Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0089216

21 January 2018

Neuropathologic correlates of apathy in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0089216

21 January 2018

Differential impact of apathy and depression in the development of dementia in mild cognitive impairment patients.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0089216

21 January 2018

Neuropsychiatric predictors of progression from amnestic-mild cognitive impairment to Alzheimer's disease: the role of depression and apathy.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0089216

21 January 2018

Patient adherence to transdermal rivastigmine after switching from oral donepezil: a retrospective claims database study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3929703

27 September 2018

Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3929703

27 September 2018

Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3929703

27 September 2018

Postnatal developmental delay and supersensitivity to organophosphate in gene-targeted mice lacking acetylcholinesterase.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3929703

27 September 2018

Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3929703

8 December 2018

Identifiers

10.1371/JOURNAL.PONE.0089216

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

2014PLoSO...989216S

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35106861&oldid=1862567717"